LOGIN
ID
PW
MemberShip
2025-07-07 07:24
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Leclaza combination therapy takes over Europe
by
Moon, sung-ho
Jul 3, 2025 06:07am
Leclaza (lazertinib), a new lung cancer drug developed by Yuhan Corporation, has been officially included in the European Society for Medical Oncology (ESMO) guidelines. Reflecting the latest clinical study findings, Leclaza in combination with Rybrevant (amivantamab, Johnson & Johnson) has been included as a first-line option in the guidelin
Company
¡®TNF-¥á inhibitors, a cornerstone for rheumatoid arthritis'
by
Whang, byung-woo
Jul 2, 2025 06:09am
Rheumatoid arthritis is a chronic autoimmune condition that causes inflammation in the joints, leading to pain and deformity. Its prevalence in Korea is estimated to be approximately 0.5&8211;1% Recently, with the development of new treatments and improved awareness of the disease, early diagnosis rates are on the rise. In fact, over the
Company
K-CAB¡¤Entresto awaiting the Supreme Court rulings
by
Kim, Jin-Gu
Jul 2, 2025 06:09am
Patent disputes involving blockbuster drugs, K-CAB (tegoprazan) and Entresto (valsartan/sacubitril), are reaching their final stages. Observations suggest that the Supreme Court's final ruling could come as early as the second half of this year. K-CAB's annual prescription sales amount to KRW 200 billion, while Entresto's are KRW 70 billion.
Company
Generics of Jardiance expected to compete for KRW 100B mkt
by
Kim, Jin-Gu
Jul 2, 2025 06:08am
The substance patent for Jardiance (empagliflozin), a diabetes treatment generating annual sales of approximately KRW 100 billion, is set to expire this October. Generic competition in the SGLT-2 inhibitor diabetes drug market is likely to heat up again. Approximately 50 companies have already secured approvals for related generic products
Company
Asthma drug 'Trelegy 200 Ellipta Inhaler' becomes available
by
Eo, Yun-Ho
Jul 1, 2025 06:03am
The asthma treatment 'Trelegy 200 Ellipta Inhaler' is now available for prescription at tertiary general hospitals. According to industry sources, Trelegy 200 Ellipta Inhaler (fluticasone furoate¡¤umeclidinium¡¤vilanterol) has passed the drug committees (DC) of Korea's 'Big 5' tertiary general hospitals, including Samsung Medical Center,
Company
Dong-A ST-Ipsen to comarket prostate cancer drug Diphereline
by
Son, Hyung Min
Jul 1, 2025 06:02am
Dong-A ST (CEO Jae-Hoon Jeong) announced on the 30th that it has signed a joint sales agreement with Ipsen Korea (CEO Mi-sun Yang) for the premature puberty and prostate cancer treatment ¡®Diphereline.¡¯ Diphereline is a GnRH (gonadotropin-releasing hormone) agonist developed by the multinational biopharmaceutical company Ipsen, used to
Company
Metabolic disease drug development landscape evolves
by
Son, Hyung Min
Jul 1, 2025 06:02am
Innovative efforts in the development of new drugs for metabolic disorders such as obesity and diabetes are steadily gaining traction in Korea and abroad. The success of standalone GLP-1 therapies has driven the evolution toward multi-hormonal agents, and recently, major global pharmaceutical companies and biotech firms are accelerating new drug
Company
AstraZeneca Korea launches ¡®Lung Health Checkbus¡¯ campaign
by
Whang, byung-woo
Jul 1, 2025 06:00am
AstraZeneca Korea announced on the 30th that it held a ceremony for the launch of its ¡®Lung Health Checkbus¡¯ campaign at the COEX Square in Seoul on the 27th. The campaign aims to help people detect lung nodules that they are not aware of at an early stage by operating buses equipped with AI-based chest X-ray imaging nationwide. Ast
Company
New K-drugs for metabolic diseases make international debut
by
Son, Hyung Min
Jun 30, 2025 06:07am
Major Korean pharmaceutical and biotechnology companies have signaled their full-scale entry into global clinical trials, presenting new drug development results at overseas conferences. The companies presented their achievements in developing new drugs for various metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction
Company
Adempas may be prescribed at general hospitals in KOR
by
Eo, Yun-Ho
Jun 30, 2025 06:06am
Adempas, a new treatment for pulmonary arterial hypertension that has emerged after a long wait, is now available for prescription at general hospitals in Korea. According to industry sources, Bayer Korea's Adempas (riociguat) has been approved by the Drug Committee (DC) of tertiary hospitals in Korea, including Samsung Medical Center and
1
2
3
4
5
6
7
8
9
10
>